Dopamine (DA) directly modulates motor circuits in the brain and spinal cord. While the somata of all dopaminergic (DAergic) neurons in zebrafish and mammals are supraspinal, some of these, termed diencephalospinal neurons (DDNs), send long-distance descending projections into the spinal cord (Figure [1A](#F1){ref-type="fig"}) and have recently been implicated in spinal network (Reimer et al., [@B10]) and locomotor development (Lambert et al., [@B8]) in zebrafish. After many years of seminal research on the morphology and genetic specification of zebrafish DDNs and the DAergic diencephalospinal tract (DDT) (Schweitzer and Driever, [@B11]), our recent study was the first to explicitly investigate DDN function (Lambert et al., [@B8]). We combined pharmacological DAergic perturbations, demarcated transections, and selective chemogenetic ablation of *orthopedia* (*otp*) neurons to demonstrate that conserved DAergic *otp* neurons--a subset of which are DDNs (Fujimoto et al., [@B3]; Figure [1A2](#F1){ref-type="fig"})---provide the impetus for endogenous DA receptor 4 (D4R) signaling to initiate and maintain a developmental switch, between 80 and 96 h post fertilization (hpf), to the mature episodic locomotor pattern of zebrafish. Interestingly, Reimer et al. ([@B10]) also demonstrated that DAergic *otp* neurons drive endogenous D4R signaling, confirmed both pharmacologically and genetically, but for an even earlier developmental function- to influence the differentiation of spinal motor progenitor cells between 24 and 48 hpf. Both studies used additional experimental approaches to demonstrate that D4R signaling directly in the spinal cord was sufficient to emulate the developmental processes under question: localized spinal application of DA or D4R agonists was shown to influence progenitor pools, when applied for many hours (Reimer et al., [@B10]), or to modulate the duration of locomotor episodes, when applied for just 5--10 min (Lambert et al., [@B8]). Collectively, these studies unveil that DDNs may drive endogenous spinal D4R signaling, via the DDT, for two temporally distinct roles in locomotor development: (1) a transient early role that acts directly on progenitor pools but not neurons, with long lasting consequences (Figure [1B](#F1){ref-type="fig"}, left), and (2) a late role that likely acts through ongoing spinal neuronal signaling, for maintenance of episodic locomotor patterns (Figure [1B](#F1){ref-type="fig"}, right). This commentary considers the extent to which an understanding of each of these developmental roles integrates with or is modified by the most recent DDN-related findings of Jay et al.

![**Descending dopaminergic control of spinal network and locomotor development. (A)** Schematics of dorsal views of the zebrafish brain and spinal cord, by 4-days-old, of: **(A1)** dopaminergic diencephalic clusters (DC) DC1-DC6. Note that DC2, DC4, and DC5 are the exclusive dopaminergic diencephalospinal neurons (DDNs) that comprise the dopaminergic diencephalospinal tract (DDT). **(A2)** orthopedia-specified neurons in the Tg(otpb.A:nfsB--egfp)^*zc*77^ line used in Lambert et al. ([@B8]), combined with systemic and localized dopamine receptor (DAR) pharmacology. **(A3)** DDNs targeted in Jay et al. ([@B6]), but with no DAR pharmacology. **(A4)** single cell morphology of DC2 DDNs that tile virtually the entire rostrocaudal central neuraxis, as well as the peripheral sensory targets of the otic capsule, lateral line, and head and trunk neuromasts. **(B)** Putative model of the role of DDN-spinal D4R signaling in: (**B**, left) spinal neuron differentiation (24--48 hpf) via direct influence on spinal motor progenitor cells (pMNS) and (**B**, right) locomotor development (80--96 hpf) via influence on unknown spinal targets. **(C)** Timeline of DDN/D4R perturbations, recovery, and testing for the studies specified. Test results denote changes, at the color-coded time of testing, in the number of HB9 motor neurons (MN), total distance traveled (TDT), and episode duration (ED) as a function of each DDN/D4R perturbation. The Otp DDN perturbation in Lambert et al. ([@B8]) was via chemogenetic ablation in the Tg(otpb.A:nfsB--egfp)^*zc*77^ line, whereas in Reimer et al. ([@B10]) was via otpa^*m*866^ mutants (where otpa expression begins at 18 hpf). All perturbations labeled as D4R were systemic pharmacological D4R antagonism/agonism, except: ![](fncel-10-00095-i0001.jpg) localized application of D4R agonist to transected spinal cord, ![](fncel-10-00095-i0002.jpg) and ![](fncel-10-00095-i0003.jpg) in addition to systemic pharmacology, recapitulated via D4Ra mRNA knockdown and rescue (respectively), ![](fncel-10-00095-i0003.jpg) recapitulated via localized application of D4R agonist to transected spinal cord in an adult zebrafish model of spinal cord injury. Abbreviations in **(A4)** denote the following: telencephalon (Telen), diencephalon (Dien), mesencephalon (Mesen), hindbrain (HB), and spinal cord (SC).](fncel-10-00095-g0001){#F1}

Since the later role of DDNs suggests a mechanism of ongoing DAergic neurotransmission to sculpt episodic locomotion, monitoring activity patterns of DDNs during neural locomotor output *in vivo* could elucidate potential DDN-spinal locomotor circuit dynamics. The recent study by Jay et al. was the first to do this in any animal model. However, activity patterns of murine DAergic mesostriatal neurons (DMNs) have been studied extensively and show that they exhibit two distinct outputs: phasic bursting that acts on low-affinity D1-like receptors, and tonic firing that acts on high-affinity D2-like receptors (Dreyer et al., [@B2]). Jay et al. found that zebrafish DDNs also exhibit phasic and tonic outputs, which plausibly may also differentially drive D1-like and D2-like signaling, respectively. Since, modulation of locomotor episode durations in zebrafish requires D2-like D4R signaling (Lambert et al., [@B8]), one would hypothesize DDN tonic firing to drive this phenomenon. Interestingly, periods of fictive locomotor activity correlated to DDN phasic bursting, but not tonic firing (Jay et al., [@B6]). However, further examination revealed that DDN phasic bursting did not reliably drive locomotor episodes or modulate their durations. Moreover, DDN tonic firing and locomotor inactivity each occurred the overwhelming majority of the time, so any correlation between the two is likely misleading. Instead, DDN tonic firing may modulate motor output---on a slower timescale---by setting spinal neuromodulatory tone (Hauber, [@B5]), rather than canonical time-locked millisecond precision to motor circuits. Taken together, if DDN activity directly influences the number and/or the duration of locomotor episodes, it likely does so via its prevalent tonic firing that is perhaps partially driven cell-autonomously.

Next, Jay et al. assessed the behavioral consequences of laser ablating DDNs (Figures [1A3,A4](#F1){ref-type="fig"}). We had previously chemogenetically ablated *otp* neurons---some of which are DDNs (Figure [1A2](#F1){ref-type="fig"})---and assessed behavioral and neural locomotor output (Lambert et al., [@B8]). Both studies found that ablation of DDNs depressed locomotor output, but only our study found an increase in the duration of individual locomotor episodes (Figure [1C](#F1){ref-type="fig"}). This discrepancy could be due to: (1) differences in timing of ablations and assessments, (2) ablation of non-DDNs in our study, and/or (3) differences in behavioral acquisition and analyses. Our study assessed behavior at 1 day post-ablation (dpa), at 5-days-old, whereas Jay et al. assessed behavior at 3 dpa, at 4-days-old. The latter may be confounded by homeostatic compensation; a recent study showed that widespread chemogenetic ablation of DAergic neurons altered multiple locomotor parameters at 1 dpa, some of which recovered by 3 dpa and coincided with newborn DAergic neurons (Godoy et al., [@B4]). Furthermore, 3 dpa of DDNs could allow for developing DAergic projections to the hindbrain to homeostatically extend into the spinal cord, or induce a shift from supraspinal (Kimura et al., [@B7]) and spinal (Lambert et al., [@B8]) modulation of episode duration, to more exclusive supraspinal control. Alternatively, it is possible that non-DDN DAergic *otp* neurons, which Jay et al. did not target, act supraspinally for the *in vivo* DAergic modulation of spontaneous episode durations that we and others have reported (Thirumalai and Cline, [@B14]; Lambert et al., [@B8]; Lange et al., [@B9]; Decker et al., [@B1]), including previous work from the same lab as in Jay et al. (Tong and McDearmid, [@B15]). While, Jay et al. did not explore any DA receptor (DAR) or localized spinal mechanisms, our study recapitulated the consquences of *otp* ablations on episode duration via systemic and localized DAR pharmacology to the transected spinal cord (Lambert et al., [@B8]); these manipulations also circumvented any caveats of recovery in the DDN or *otp* ablation experiments (Figure [1C](#F1){ref-type="fig"}). Aside from any of the above, the discrepancy of behavioral results between studies could simply be due to our study recording multiple fish in a 50 mm arena, compared to Jay et al. recording fish in isolation in a five-fold smaller arena. Each study also employed different definitions and detections of free-swimming episode durations. Moreover, higher acquisition rates increase fidelity of episodic structure, and Jay et al. only acquired videos at 15 Hz whereas we acquired at 60 Hz. Additionally, we also confirmed altered fictive episode durations acquired at 10,000 Hz.

Independent of any role of DDNs in episode duration, it is not clear whether Jay et al.\'s result of depressed locomotor output at 3 dpa of DDNs is linked to the loss of ongoing DDN neuronal activity at 4-days-old, or is simply a long-term consequence of perturbing the early influence of DDNs on progenitor pools from 24 to 48 hpf (Figure [1C](#F1){ref-type="fig"}). Reimer et al. ([@B10]) showed that transiently blocking endogenous D4R signaling from 24 to 72 hpf resulted in depressed locomotor output 6 days later that coincided with altered spinal neuronal distributions (Figure [1C](#F1){ref-type="fig"}). Hence, future studies interrogating the role of ongoing DDN neuronal activity on locomotor output should ablate or optogenetically manipulate DDNs only after the critical period for early DDN influence of progenitor pools has passed.

Finally, an inherent caveat of investigating the function of vertebrate DDNs is that their conserved morphology tiles most of the rostrocaudal extent of the central nervous system, from telencephalon to spinal cord (Takada et al., [@B12]; Tay et al., [@B13]; Figure [1A4](#F1){ref-type="fig"}). As such, it is plausible that DDNs simultaneously modulate spatially disparate postsynaptic targets, both spinally and supraspinally. Additionally, Jay et al. elegantly revealed that DDNs also likely innervate peripheral sensory structures (Figure [1A4](#F1){ref-type="fig"}). Hence, future studies testing whether DDNs directly modulate spinal locomotor circuits *in vivo* should circumvent any potential DDN influences on supraspinal or peripheral DAergic signaling. This could be achieved via laser ablation or optogenetic manipulation of DDT axons specifically at the level of the spinal cord. It will be then that sources of spinal DA can finally speak unambiguously about their spinal locomotor influences.
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